Although its validity as a marker of BBB disruption has been questioned [77], meta-analyses have reported that schizophrenia patients have higher serum S100B concentrations than controls [78,79] and that there is a positive correlation between S100B levels and positive symptoms, total psychopathology scores, and duration of psychotic illness [79]. The gene discussed is S100B; the disease is schizophrenia.